<DOC>
	<DOCNO>NCT02579603</DOCNO>
	<brief_summary>This phase IV , twelve week , open label , randomize , parallel group study assess safety tolerability combine treatment nintedanib pirfenidone . A secondary objective ass exposure base PK trough concentration value nintedanib either give alone combination pirfenidone ass exposure pirfenidone combine nintedanib .</brief_summary>
	<brief_title>Safety , Tolerability PK Nintedanib Combination With Pirfenidone IPF</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Inclusion criterion : Written inform consent consistent ICHGCP local law , sign prior study procedure perform ( include require washout ) Male female patient age great equal 40 year visit 1 Idiopathic Pulmonary Fibrosis ( IPF ) diagnosis , base upon ATS/ERS/JRS/ALAT 2011 guideline confirm investigator base chest high resolution compute tomography ( HRCT ) scan perform within 12 month visit 1 FVC great equal 50 % predict normal visit 1 Exclusion criterion : ALT , AST &gt; 1.5 fold upper limit normal ( ULN ) visit 1 Total bilirubin &gt; 1.5 fold ULN visit 1 Relevant airway obstruction ( i.e . prebronchodilator FEV1/FVC &lt; 0.7 ) visit 1 History myocardial infarction within 6 month visit 1 unstable angina within 1 month visit 1 Bleeding Risk : Known genetic predisposition bleeding , Patients require fibrinolysis , fulldose therapeutic anticoagulation ( e.g . vitamin K antagonist , dabigatran , heparin , hirudin etc ) high dose antiplatelet therapy , History haemorrhagic central nervous system event within 12 month prior visit 1 , History haemoptysis haematuria , active gastrointestinal bleeding ulcer and/or major injury surgery within 3 month prior visit 1 , International normalise ratio ( INR ) &gt; 2 visit 1 , Prothrombin time partial thromboplastin time ( PTT ) &gt; 150 % institutional ULN visit 1 Planned major surgery trial participation , include lung transplantation , major abdominal major intestinal surgery . History thrombotic event ( include stroke transient ischemic attack ) within 12 month visit 1 Severe renal impairment ( Creatinine clearance &lt; 30 mL/min calculate CockcroftGault formula visit 1 ) endstage renal disease require dialysis . Treatment NAC , prednisone &gt; 15 mg daily &gt; 30 mg every 2 day OR equivalent dose oral corticosteroid and/or fluvoxamine within 2 week visit 2 Treatment azathioprine , cyclophosphamide , cyclosporine well investigational drug within 8 week visit 2 Previous treatment pirfenidone Permanent discontinuation nintedanib past due AEs consider drugrelated Known hypersensitivity nintedanib , pirfenidone , peanut soya excipients A disease condition opinion investigator may interfere test procedure put patient risk participate trial Alcohol drug abuse opinion treat physician would interfere treatment Women pregnant , nursing , plan become pregnant trial . Women childbearing potential willing able use highly effective method birth control per ICH M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly5 28 day prior 3 month nintedanib administration Patients able understand follow study procedure include completion selfadministered questionnaire without help Patients require dose reduction and/or temporary interruption runin period nintedanib 150 mg bid Patients underlie chronic liver disease ( Child Pugh A , B C hepatic impairment )</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>